<p>STAAR Surgical（納斯達克代碼：STAA - 獲取免費報告）於週三發佈了季度財報。這家醫療器械供應商報告本季度每股收益為 0.17 美元，低於分析師一致預期的 0.18 美元，差距為 0.01 美元，Briefing.com 報道。STAAR Surgical 的股本回報率為-16.11%，淨利潤率為-42.45%。該公司本季度的收入為 9470 萬美元，而分析師預期為 9215 萬美元。去年同期，該公司每股收益為 0.20 美元。</p>
<p>獲取 <strong>STAAR Surgical</strong> 警報：</p>
<h2>STAAR Surgical 股票表現</h2>
<ul>
<li>內部人士顯著增持的前四隻股票</li>
</ul>
<p>週五中午，STAA 股票下跌 0.63 美元，報 25.90 美元。該公司交易了 633,128 股，低於其平均交易量 1,183,428 股。該公司的市值為 12.8 億美元，市盈率為-13.42，貝塔值為 0.82。STAAR Surgical 的 52 周低點為 13.50 美元，52 周高點為 32.00 美元。該公司的 50 日簡單移動平均線為 26.96 美元，200 日簡單移動平均線為 21.88 美元。</p>
<h2>對 STAAR Surgical 的對沖基金看法</h2>
<p>對沖基金最近買入和賣出了該公司的股票。Soleus Capital Management L.P.在第二季度增持了 STAAR Surgical 的股份，增幅為 16.5%。Soleus Capital Management L.P.目前擁有 2,984,733 股該醫療器械供應商的股票，價值 50,084,000 美元，此前在該期間內又購買了 421,840 股。美國銀行在第二季度增持了 STAAR Surgical 的股份，增幅為 17.1%。美國銀行目前擁有 1,153,895 股該醫療器械供應商的股票，價值 19,362,000 美元，此前在該期間內又購買了 168,285 股。高盛集團在第一季度增持了 STAAR Surgical 的股份，增幅為 33.4%。高盛集團目前擁有 544,843 股該醫療器械供應商的股票，價值 9,606,000 美元，此前在該期間內又收購了 136,390 股。Federated Hermes Inc.在第二季度新建了 STAAR Surgical 的股份，價值 6,095,000 美元。最後，法國巴黎銀行金融市場在第二季度增持了 STAAR Surgical 的股份，增幅為 322.4%。法國巴黎銀行金融市場目前擁有 243,470 股該醫療器械供應商的股票，價值 4,085,000 美元，此前在該期間內又購買了 185,836 股。目前 96.70% 的股票由機構投資者和對沖基金持有。</p>
<h2>分析師評級上調和下調</h2>
<ul>
<li>隨着 2024 年美國前景改善，Star Surgical 表現出色</li>
</ul>
<p>幾位研究分析師對該公司發表了看法。Piper Sandler 在週一的報告中重申了對 STAAR Surgical 股票的 “中性” 評級。Canaccord Genuity Group 在 10 月 21 日的研究報告中重新發布了 “持有” 評級，並設定了 28.00 美元的目標價。Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 STAAR Surgical 股票的 “賣出（d）” 評級。Stifel Nicolaus 在 8 月 7 日的研究報告中設定了 STAAR Surgical 股票的 28.00 美元價格目標，並給予該股票 “持有” 評級。最後，瑞穗證券在 7 月 16 日的報告中將 STAAR Surgical 的目標價從 17.00 美元上調至 18.00 美元，並給予該公司 “中性” 評級。十位股票研究分析師對該股票給予了 “持有” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “減持”，共識目標價為 20.67 美元。</p>
<p><strong>查看我們對 STAAR Surgical 的最新股票分析</strong></p>
<h2>STAAR Surgical 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>STAAR Surgical 公司及其子公司設計、開發、製造、營銷和銷售用於眼睛的植入式鏡片及其伴隨的輸送系統，以將鏡片送入眼睛。該公司提供植入式 Collamer 鏡片產品系列（ICLs），用於治療視覺障礙，如近視、遠視、散光和老花眼。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們更看好的股票，勝過 STAAR Surgical</li>
<li>如何做空納斯達克：易於遵循的指南</li>
<li>Equinix 股票儘管下調收入指引仍上漲</li>
<li>期權交易 - 理解行使價格</li>
<li>MongoDB：這不是騙局，這個 AI 項目是個好消息</li>
<li>投資 5G 技術的頂級股票</li>
<li>140 億美元的日本工廠標誌着台積電的大膽 AI 戰略</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 STAAR Surgical 嗎？</h2>
<p>在考慮 STAAR Surgical 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 STAAR Surgical 並不在名單上。</p>
<p>雖然 STAAR Surgical 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

達視光學

<p>STAAR Surgical（納斯達克代碼：STAA）報告的季度每股收益為 0.17 美元，低於預期的 0.18 美元。該公司的收入為 9470 萬美元，超過了 9215 萬美元的預期。STAAR Surgical 的股本回報率為負 16.11%，淨利潤率為 42.45%。股票交易價格下跌至 25.90 美元，市值為 12.8 億美元。分析師的評級意見不一，普遍評級為 “減持”，目標價格為 20.67 美元。機構投資者持有該股票的 96.70%</p>

<p>STAAR Surgical (NASDAQ:STAA - Get Free Report) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01), Briefing.com reports. STAAR Surgical had a negative return on equity of 16.11% and a negative net margin of 42.45%.The company had revenue of $94.70 million during the quarter, compared to analyst estimates of $92.15 million. During the same period last year, the firm earned $0.20 earnings per share.</p>
<div class="lb-trans"><p>STAAR Surgical（納斯達克代碼：STAA - 獲取免費報告）於週三發佈了季度財報。這家醫療器械供應商報告本季度每股收益為 0.17 美元，低於分析師一致預期的 0.18 美元，差距為 0.01 美元，Briefing.com 報道。STAAR Surgical 的股本回報率為-16.11%，淨利潤率為-42.45%。該公司本季度的收入為 9470 萬美元，而分析師預期為 9215 萬美元。去年同期，該公司每股收益為 0.20 美元。</p>
</div><p>Get <strong>STAAR Surgical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>STAAR Surgical</strong> 警報：</p>
</div><h2>STAAR Surgical Stock Performance</h2>
<div class="lb-trans"><h2>STAAR Surgical 股票表現</h2>
</div><ul>
<li>Top 4 Stocks With Notable Insider Buying</li>
</ul>
<div class="lb-trans"><ul>
<li>內部人士顯著增持的前四隻股票</li>
</ul>
</div><p>Shares of STAA stock traded down $0.63 during mid-day trading on Friday, reaching $25.90. 633,128 shares of the company were exchanged, compared to its average volume of 1,183,428. The company has a market capitalization of $1.28 billion, a P/E ratio of -13.42 and a beta of 0.82. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $32.00. The business's 50 day simple moving average is $26.96 and its 200 day simple moving average is $21.88.</p>
<div class="lb-trans"><p>週五中午，STAA 股票下跌 0.63 美元，報 25.90 美元。該公司交易了 633,128 股，低於其平均交易量 1,183,428 股。該公司的市值為 12.8 億美元，市盈率為-13.42，貝塔值為 0.82。STAAR Surgical 的 52 周低點為 13.50 美元，52 周高點為 32.00 美元。該公司的 50 日簡單移動平均線為 26.96 美元，200 日簡單移動平均線為 21.88 美元。</p>
</div><h2>Hedge Funds Weigh In On STAAR Surgical</h2>
<div class="lb-trans"><h2>對 STAAR Surgical 的對沖基金看法</h2>
</div><p>Hedge funds have recently bought and sold shares of the company. Soleus Capital Management L.P. boosted its holdings in STAAR Surgical by 16.5% in the second quarter. Soleus Capital Management L.P. now owns 2,984,733 shares of the medical instruments supplier's stock worth $50,084,000 after purchasing an additional 421,840 shares during the period. Bank of America Corp DE boosted its position in STAAR Surgical by 17.1% during the 2nd quarter. Bank of America Corp DE now owns 1,153,895 shares of the medical instruments supplier's stock valued at $19,362,000 after purchasing an additional 168,285 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of STAAR Surgical by 33.4% during the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier's stock valued at $9,606,000 after acquiring an additional 136,390 shares during the period. Federated Hermes Inc. acquired a new position in shares of STAAR Surgical during the second quarter valued at $6,095,000. Finally, BNP Paribas Financial Markets boosted its stake in STAAR Surgical by 322.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 243,470 shares of the medical instruments supplier's stock valued at $4,085,000 after purchasing an additional 185,836 shares during the period. 96.70% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>對沖基金最近買入和賣出了該公司的股票。Soleus Capital Management L.P.在第二季度增持了 STAAR Surgical 的股份，增幅為 16.5%。Soleus Capital Management L.P.目前擁有 2,984,733 股該醫療器械供應商的股票，價值 50,084,000 美元，此前在該期間內又購買了 421,840 股。美國銀行在第二季度增持了 STAAR Surgical 的股份，增幅為 17.1%。美國銀行目前擁有 1,153,895 股該醫療器械供應商的股票，價值 19,362,000 美元，此前在該期間內又購買了 168,285 股。高盛集團在第一季度增持了 STAAR Surgical 的股份，增幅為 33.4%。高盛集團目前擁有 544,843 股該醫療器械供應商的股票，價值 9,606,000 美元，此前在該期間內又收購了 136,390 股。Federated Hermes Inc.在第二季度新建了 STAAR Surgical 的股份，價值 6,095,000 美元。最後，法國巴黎銀行金融市場在第二季度增持了 STAAR Surgical 的股份，增幅為 322.4%。法國巴黎銀行金融市場目前擁有 243,470 股該醫療器械供應商的股票，價值 4,085,000 美元，此前在該期間內又購買了 185,836 股。目前 96.70% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><ul>
<li>Star Surgical Shines as U.S. Outlook Improves for 2024</li>
</ul>
<div class="lb-trans"><ul>
<li>隨着 2024 年美國前景改善，Star Surgical 表現出色</li>
</ul>
</div><p>Several research analysts have weighed in on the company. Piper Sandler reiterated a &#34;neutral&#34; rating on shares of STAAR Surgical in a report on Monday. Canaccord Genuity Group reissued a &#34;hold&#34; rating and set a $28.00 target price on shares of STAAR Surgical in a research report on Tuesday, October 21st. Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of STAAR Surgical in a research report on Wednesday, October 8th. Stifel Nicolaus set a $28.00 price objective on shares of STAAR Surgical and gave the stock a &#34;hold&#34; rating in a research report on Thursday, August 7th. Finally, Mizuho increased their price target on STAAR Surgical from $17.00 to $18.00 and gave the company a &#34;neutral&#34; rating in a report on Wednesday, July 16th. Ten equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Reduce&#34; and a consensus price target of $20.67.</p>
<div class="lb-trans"><p>幾位研究分析師對該公司發表了看法。Piper Sandler 在週一的報告中重申了對 STAAR Surgical 股票的 “中性” 評級。Canaccord Genuity Group 在 10 月 21 日的研究報告中重新發布了 “持有” 評級，並設定了 28.00 美元的目標價。Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 STAAR Surgical 股票的 “賣出（d）” 評級。Stifel Nicolaus 在 8 月 7 日的研究報告中設定了 STAAR Surgical 股票的 28.00 美元價格目標，並給予該股票 “持有” 評級。最後，瑞穗證券在 7 月 16 日的報告中將 STAAR Surgical 的目標價從 17.00 美元上調至 18.00 美元，並給予該公司 “中性” 評級。十位股票研究分析師對該股票給予了 “持有” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “減持”，共識目標價為 20.67 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on STAAR Surgical</strong></p>
<div class="lb-trans"><p><strong>查看我們對 STAAR Surgical 的最新股票分析</strong></p>
</div><h2>STAAR Surgical Company Profile</h2>
<div class="lb-trans"><h2>STAAR Surgical 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.</p>
<div class="lb-trans"><p>STAAR Surgical 公司及其子公司設計、開發、製造、營銷和銷售用於眼睛的植入式鏡片及其伴隨的輸送系統，以將鏡片送入眼睛。該公司提供植入式 Collamer 鏡片產品系列（ICLs），用於治療視覺障礙，如近視、遠視、散光和老花眼。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than STAAR Surgical</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>Equinix Stock Rises Despite Lower Revenue Guidance</li>
<li>Options Trading - Understanding Strike Price</li>
<li>MongoDB: It’s No Trick, This AI Play Is a Treat</li>
<li>Top Stocks Investing in 5G Technology</li>
<li>$14B Japanese Facility Signals TSMC's Bold AI Strategy</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 STAAR Surgical</li>
<li>如何做空納斯達克：易於遵循的指南</li>
<li>Equinix 股票儘管下調收入指引仍上漲</li>
<li>期權交易 - 理解行使價格</li>
<li>MongoDB：這不是騙局，這個 AI 項目是個好消息</li>
<li>投資 5G 技術的頂級股票</li>
<li>140 億美元的日本工廠標誌着台積電的大膽 AI 戰略</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1RBQQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=STAA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in STAAR Surgical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 STAAR Surgical 嗎？</h2>
</div><p>Before you consider STAAR Surgical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 STAAR Surgical 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前進行購買……而 STAAR Surgical 並不在名單上。</p>
</div><p>While STAAR Surgical currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 STAAR Surgical 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

達視光學（NASDAQ:STAA）公佈財報結果